Population pharmacokinetics of arbekacin, vancomycin, and panipenem in neonates
Toshimi Kimura1, Keisuke Sunakawa, Nobuo Matsuura
1Department of Pharmacy, Kitasato University Hospital, 1-15-1 Kitasato, Sagamihara-shi, Kanagawa 228-8555, Japan. gr4t-kmr@asahi-net.or.jp
Insights
Neonates require adjusted antibiotic doses due to immature kidney function. This study developed pharmacokinetic models for arbekacin, vancomycin, and panipenem, providing formulas for optimal dosing based on postconceptional age and weight.
Area of Science:
- Pharmacology
- Neonatal Medicine
- Clinical Pharmacy
Background:
- Neonates possess immature renal function, necessitating precise antibiotic dosage adjustments.
- Accurate dosing is crucial for therapeutic efficacy and minimizing toxicity in this vulnerable population.
Purpose of the Study:
- To establish optimal antibiotic dosage regimens for neonates.
- To determine population pharmacokinetic parameters for arbekacin, vancomycin, and panipenem.
Main Methods:
- Population pharmacokinetic analysis using a one-compartment open model with first-order elimination.
- Nonlinear mixed-effect modeling was employed to evaluate pharmacokinetic parameters.
- Data from 83 neonates with varying postconceptional ages (PCAs) and body weights (BWs) were analyzed.
Main Results:
- Clearance (CL) of antibiotics was significantly influenced by PCA, postnatal age, gestational age, BW, and serum creatinine.
- Volume of distribution (V) was primarily influenced by BW.
- Specific formulas were derived for arbekacin, vancomycin, and panipenem CL and V based on PCA and BW.
Conclusions:
- Antibiotic clearance in neonates increases exponentially with postconceptional age, reflecting the maturation of glomerular filtration.
- Clinicians must consider PCA, serum creatinine, BW, and drug properties for accurate neonatal antibiotic dosing.
- The developed pharmacokinetic models provide a basis for optimizing antibiotic therapy in neonates.
Abstract:
Immature renal function in neonates requires antibiotic dosage adjustment. Population pharmacokinetic studies were performed to determine the optimal dosage regimens for three types of antibiotics: an aminoglycoside, arbekacin; a glycopeptide, vancomycin; and a carbapenem, panipenem. Eighty-three neonates received arbekacin (n = 41), vancomycin (n = 19), or panipenem (n = 23). The postconceptional ages (PCAs) were 24.1 to 48.4 weeks, and the body weights (BWs) ranged from 458 to 5,200 g. A one-compartment open model with first-order elimination was applied and evaluated with a nonlinear mixed-effect model for population pharmacokinetic analysis. In the fitting process, the fixed effects significantly related to clearance (CL) were PCA, postnatal age, gestational age, BW, and serum creatinine level; and the fixed effect significantly related to the volume of distribution (V) was BW. The final formulas for the population pharmacokinetic parameters are as follows: CL(arbekacin) = 0.0238 x BW/serum creatinine level for PCAs of <33 weeks and CL(arbekacin) = 0.0367 x BW/serum creatinine level for PCAs of > or = 33 weeks, V(arbekacin) = 0.54 liters/kg, CL(vancomycin) = 0.0250 x BW/serum creatinine level for PCAs of <34 weeks and CL(vancomycin) = 0.0323 x BW/serum creatinine level for PCAs of > or = 34 weeks, V(vancomycin) = 0.66 liters/kg, CL(panipenem) = 0.0832 for PCAs of <33 weeks and CL(panipenem) = 0.179 x BW for PCAs of > or = 33 weeks, and V(panipenem) = 0.53 liters/kg. When the CL of each drug was evaluated by the nonlinear mixed-effect model, we found that the mean CL for subjects with PCAs of <33 to 34 weeks was significantly smaller than those with PCAs of > or = 33 to 34 weeks, and CL showed an exponential increase with PCA. Many antibiotics are excreted by glomerular filtration, and maturation of glomerular filtration is the most important factor for estimation of antibiotic clearance. Clinicians should consider PCA, serum creatinine level, BW, and chemical features when determining the initial antibiotic dosing regimen for neonates.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Pharmacokinetics in Pediatric Patients: Drug Distribution
Estimation of k and VD of Aminoglycosides
Drug Dosing: Infants and Children

